De la Rosa Carrillo, DavidMartínez-García, Miguel ÁngelBarreiro, EstherTabernero Huguet, EvaCosta Sola, RoserGarcía-Clemente, Marta MaríaCelorrio Jiménez, NuriaRodríguez Pons, LauraCalero Acuña, CarmenRodríguez Hermosa, Juan LuísGolpe, RafaelDacal Quintas, RaquelSánchez-Cuéllar, SilviaTorres Arroyo, IreneBlanco Aparicio, MarinaAlmadana Pacheco, VirginiaMiravitlles, MarcStudy group on the effectiveness of inhaled antibiotic treatment in COPDStudy group on the effectiveness of inhaled antibiotic treatment in COPD2023-05-032023-05-032021-03-19http://hdl.handle.net/10668/21983We aimed to describe the effectiveness and safety of inhaled antibiotics in chronic obstructive pulmonary disease (COPD) patients, as well as the patient profile in which they are usually prescribed and the patient groups that can most benefit from this treatment. Multicentre retrospective observational cohort study in COPD patients who had received ≥1 dose of inhaled antibiotics in the last 5 years. Clinical data from the two years prior to and subsequent to the start of the treatment were compared. COPD exacerbations. side effects, symptomatology (sputum purulence, dyspnoea), microbiological profile and pathogen eradication. Of 693 COPD patients analyzed (aged 74.1; 86.3% men; mean FEV1=43.7%), 71.7% had bronchiectasis and 46.6% presented chronic bronchial infection (CBI) by Pseudomonas aeruginosa (PA). After 1 year of treatment with inhaled antibiotics, there was a significant decrease in the number of exacerbations (-33.3%; P In COPD patients with multiple exacerbations and/or CBI by any PPM (especially PA), inhaled antibiotics appear to be an effective and safe treatment, regardless of the presence of bronchiectasis.enAntibióticos inhaladosBronchiectasisBronquiectasiaChronic bronchial infectionChronic obstructive pulmonary diseaseEnfermedad pulmonar obstructiva crónicaExacerbacionesExacerbationsInfección bronquial crónicaInhaled antibioticsPseudomonas aeruginosaresearch article3384972110.1016/j.arbres.2021.03.0091579-2129